BridgeBio Pharma
BBIO
BBIO
95 hedge funds and large institutions have $3.28B invested in BridgeBio Pharma in 2020 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 42 increasing their positions, 16 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
95
Holders Change
+7
Holders Change %
+7.95%
% of All Funds
2.1%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.13%
New
25
Increased
42
Reduced
16
Closed
16
Calls
$11.3M
Puts
$3.19M
Net Calls
+$8.08M
Net Calls Change
+$8.08M
Top Buyers
| 1 |
BlackRock
New York
|
+$74.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$26.3M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$13.7M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$12.7M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$10.9M |
Top Sellers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$39.3M |
| 2 |
AIG
American International Group
New York
|
-$23.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.4M |
| 4 |
Nuveen Asset Management
Chicago,
Illinois
|
-$4.28M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.75M |
